Estimating the Direct and Indirect Costs of ADHD in Canada

This project will provide an estimate of the direct and indirect costs of ADHD in Canada. The peer-reviewed report will be used by the partner organization to appeal to the different levels of government to publicly fund ADHD treatment in Canada. An existing model, developed by Takeda Pharmaceuticals, will be adjusted to the Canadian context. The model will use cost-benefit analysis principles to determine how much ADHD is costing the Canadian economy, and how much money can be saved if the target rate of 70% of ADHD patients receives treatment. The partner organization will benefit as they will use the findings of the research project in their field of work will be co-authors on a peer-reviewed research article.

Faculty Supervisor:

Emmanuelle Piérard

Student:

Partner:

Canadian ADHD Resource Alliance

Discipline:

Sociology

Sector:

Education

University:

University of Waterloo

Program: